Find any stock by ticker or company name
Barcha huquqlar himoyalangan.
0.12
0.00 (0.00%)
LAS VEGAS, NEVADA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”) and Austrianova, its joint venture partner in Insulinova, today announced that Insulinova has entered into a Research and Option Agreement with Ospedale San Raffaele S.r.l. (OSR), a leading European biomedical research institution, to collaborate on the development of an encapsulated cell therapy for the treatment of Type 1 and insulin-dependent Type 2 diabetes.
There is no data to display
